


Atabecestat

Chemical Properties

CAS No. :	1200493-78-2
Formula:	C ₁₈ H ₁₄ FN ₅ O ₅
Molecular Weight:	367.4
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Atabecestat (JNJ-54861911) is a potent, brain-penetrant, and orally active β -site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor that achieves robust and high CSF A β reduction, is well-tolerated, and displays sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat (JNJ-54861911) has the potential for Alzheimer's Disease treatment[1].
Targets(IC50)	Beta-Secretase,BACE
In vivo	In 5-week-old APPPS1 mice, Atabecestat (100 and 300 mg/kg; oral gavage; once daily for 3 days) reduced the levels of human A β 1-40 and A β 1-42 in the brain of APPPS1 mice at a dose of 300 mg/kg, and resulted in less reduction of human A β levels at 24 hours with a dose of 100 mg/kg[2].

Solubility Information

Solubility	DMSO: 200 mg/mL (544.37 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.7218 mL	13.6091 mL	27.2183 mL
5 mM	0.5444 mL	2.7218 mL	5.4437 mL
10 mM	0.2722 mL	1.3609 mL	2.7218 mL
50 mM	0.0544 mL	0.2722 mL	0.5444 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Timmers M, et al. Profiling the dynamics of CSF and plasma A β reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. *Alzheimers Dement (N Y)*. 2016 Aug 24;2(3):202-212.

Janssens J, et al. Passive immunotherapy with a novel antibody against 3pE-modified A β demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice. *Neurobiol Dis*. 2021 Jul;154:105365.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481